MetaCap

Alterity Therapeutics (ATHE) vs ProMIS Neurosciences (PMN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alterity Therapeutics (ATHE) has outperformed ProMIS Neurosciences (PMN) over the past year, losing 56.7% versus a loss of 69.9%. Over five years, ATHE leads with a -85.4% price change compared with -98.2% for PMN. Alterity Therapeutics is the larger company by market cap ($29.0 million vs $28.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATHE-56.70%PMN-69.90%
+146%+32%-82%
Nov 21, 20251 yearNov 20, 2026
ATHE-85.93%PMN-98.38%
+24%-40%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATHE versus PMN key metrics
MetricATHEPMN
Share price$1.52$3.16
Market cap$29.02M$28.43M
1-day change-8.16%-1.56%
YTD return-50.65%-53.73%
1-year return-56.70%-69.90%
5-year return-85.38%-98.24%
EPS (TTM)$-0.90$-6.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-39.72M
52-week high$5.89$27.40
52-week low$1.52$2.78
Distance from 52-week high-74.19%-88.47%
Analyst consensusnonenone
Avg. price target upside+771.71%+1248.42%
Average volume89.63K164.88K
Shares outstanding19.09M9.00M
Employees1110
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ATHE has outperformed PMN by 13.2 percentage points over the past year.

About Alterity Therapeutics

ATHE stock →

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees

About ProMIS Neurosciences

PMN stock →

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

ATHE vs PMN FAQ

Which is bigger, Alterity Therapeutics or ProMIS Neurosciences?

Alterity Therapeutics (ATHE) is larger, with a market capitalization of $29.02M compared with $28.43M for ProMIS Neurosciences (PMN).

Which stock has performed better over the past year, ATHE or PMN?

ATHE returned -56.70% over the past 12 months, compared with -69.90% for PMN (price return, excluding dividends). Past performance does not predict future results.

Are Alterity Therapeutics and ProMIS Neurosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons